Zydus Lifesciences Ltd
Announcement under Regulation 30 (LODR)-Press Release / Media Release
01:28 PM, 18th Jan 2025
Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS).
